Board will provide the necessary guidance as cancer immunotherapy company prepares for its lead Moditope candidate to enter the clinic in 2020
Scancell Holdings has appointed six world-leading clinicians to establish its Clinical Advisory Board (CAB). The Board will be chaired by Professor Robert Coleman and will provide strategic guidance and support. This will be especially needed as the cancer immunotherapy company prepares for its lead Moditope candidate, Modi-1, to enter the clinic in Q1 2020 in multiple tumour types, including head and neck, breast and ovarian cancer.
The CAB comprises:
Scancell also provided an update on progress towards initiating the Modi-1 Phase 1/2 clinical trial:
Scancell’s Moditope platform acts by stimulating the production of CD4 T cells using citrullinated tumour-associated peptide epitopes. This technology overcomes the immune suppression induced by tumours themselves, allowing activated T-cells to seek out and kill tumour cells that would otherwise be hidden from the immune system.
Previous pre-clinical data demonstrated that conjugation of the Modi-1 peptides to Amplivant enhances anti-tumour immune responses 10-100 fold and resulted in highly efficient tumour eradication, including protection against tumour recurrence.
Dr Cliff Holloway, Scancell CEO, said: “The creation of this Board is part of our wider strategy to fully develop and deliver the full potential of the Moditope platform across multiple tumour types.”
Holloway added: “The initial focus of the Board will be to inform the clinical strategy for the planned Modi-1 clinical trial and to ensure the best possible outcome in several solid tumour indications, including ovarian cancer, head and neck cancer, and triple negative breast cancer. Significant progress has been made towards completing the GMP manufacture of the Modi-1 product and the preclinical testing required prior to the anticipated start of the trial early in 2020.”